Additional Study Information: This is a first in human study. You will be given an investigational drug called FHD-286. FHD-286 is not approved by the U.S. Food and Drug Administration (FDA) or other regulatory authorities around the world for the treatment of cancer or any other disease. The purpose of this study is to determine the safety and tolerability of FHD-286 when given to patients with metastatic uveal melanoma. The first phase, or escalation phase, of the study will determine the safe dose for the second phase, or expansion phase, of the study. The primary goal of the expansion phase is to further evaluate the safety of the study drug in patients with metastatic UM. This study will also evaluate the behavior of the study drug in the body and in the tumor(s).